One-hour special – The President of the PBOA

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA).

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering:

• The evolution of the PBOA over the last decade, the impact of M&A on the Association, and building a safe place where CDMOs belong
• How the industry has evolved over the last few years after Covid, including harder times and areas of green shoots
• Why Gil believes Novo‘s purchase of Catalent is a black swan event and not a new megatrend
• A deeper dive into fine details of The BIOSECURE Act, and its potential impact on the CDMO space over the next 7-8 years
• The need to know market headwinds and tailwinds that you simply cannot ignore

Gil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA’s annual members-only Meeting & Conference.

Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called the Virtual Memories Show (https://chimeraobscura.com/vm)

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.